Chemical compound
Moxazocine
(1S ,9R ,13S )-10-(cyclopropylmethyl)-13-methoxy-1-methyl-10-azatricyclo[7.3.1.02,7 ]trideca-2,4,6-trien-4-ol
CAS Number ChemSpider UNII Formula C 18 H 25 N O 2 Molar mass 287.403 g·mol−1 3D model (JSmol )
Oc1ccc2C[C@H]3N(CC[C@@](C)(c2c1)[C@@H]3OC)CC4CC4
InChI=1S/C18H25NO2/c1-18-7-8-19(11-12-3-4-12)16(17(18)21-2)9-13-5-6-14(20)10-15(13)18/h5-6,10,12,16-17,20H,3-4,7-9,11H2,1-2H3/t16-,17-,18+/m1/s1
Key:IOZWXJXXVLARQC-KURKYZTESA-N
Moxazocine (BL-4566 ) is an opioid analgesic of the benzomorphan family which was never marketed.[1] It acts as a partial agonist or mixed agonist /antagonist of the opioid receptors and binds preferentially to the κ-opioid receptor .[2] Despite its failure to reach the market, clinical studies demonstrated moxazocine to be approximately 10x as potent by weight as morphine as an analgesic.[3]
Synthesis [ ]
Reduction of the carbonyl group in oxygenated benzomorphan 1 affords the corresponding alcohol (2 ). This intermediate is then N-demethylated by means of BrCN . Acylation with [5] [6] gives the amide (3 ). The alcohol is then converted to the ether by treatment with MeI and base (4 ). Treatment with LiAlH4 serves to reduce the amide function. Cleavage of the phenolic ether by one of the standard schemes affords moxazocine (6 ).
See also [ ]
References [ ]
^ Dictionary of Pharmacological Agents Volume 2 . CRC Press. 1996-11-21. p. 1382. ISBN 978-0-412-46630-4 . Retrieved 22 April 2012 .
^ Hayes AG, Sheehan MJ, Tyers MB (August 1987). "Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists" . British Journal of Pharmacology . 91 (4): 823–32. doi :10.1111/j.1476-5381.1987.tb11281.x . PMC 1853585 . PMID 2822190 .
^ Dobkin, Allen B; Esposito, Barbara F; Noveck, Robert J; Caruso, Frank S (October 1977). "Moxazocine and morphine in patients with severe postoperative pain" . Current Therapeutic Research . 22 (4): 469–478. CS1 maint: uses authors parameter (link )
^ T. A. Montzka and J. D. Matiskella, DE 2517220 Chem. Abstr. 84, 59832k (1976).
^ Zhang, Kexun; Lu, Ming; Li, Yeqing (2003). "Synthesis of Cyclopropanecarbonyl chloride" . Chemical Industry Times . 17 (7): 36–38.
^ U.S. Patent 5,504,245
Analgesics (N02A , N02B )
Opioids
Opiates /opium
Codeine #
Morphine # (+naltrexone )
Opium
Laudanum
Paregoric
Semisynthetic Synthetic
Paracetamol -typeNSAIDs
Propionates Oxicams
Isoxicam
Lornoxicam
Meloxicam
Piroxicam
Tenoxicam
Acetates COX-2 inhibitors Fenamates Salicylates
Aspirin (acetylsalicylic acid) # (+paracetamol/caffeine )
Benorylate
Diflunisal
Ethenzamide
Magnesium salicylate
Salicin
Salicylamide
Salsalate
Wintergreen (methyl salicylate )
Pyrazolones
Aminophenazone ‡
Ampyrone
Metamizole (dipyrone)
Nifenazone
Phenazone
Propyphenazone (+paracetamol/caffeine )
Others
Cannabinoids
Cannabidiol
Cannabis
Nabilone
Nabiximols
Tetrahydrocannabinol (dronabinol)
Ion channel modulators
Calcium blockers
Alcohol (ethanol)
Gabapentin
Gabapentin enacarbil
Leconotide
Mirogabalin
Pregabalin
Ziconotide
Sodium blockers
Carbamazepine
Lacosamide
Local anesthetics (e.g., cocaine , lidocaine )
Mexiletine
Nefopam
Tricyclic antidepressants (e.g., amitriptyline # )
Nav 1.7/1.8-selective: DSP-2230 §
Funapide §
PF-05089771 §
Potassium openers
Myorelaxants
Carisoprodol
Chlorzoxazone
Cyclobenzaprine
Mephenoxalone
Methocarbamol
Orphenadrine
Others
# WHO-EM
‡ Withdrawn from market
Clinical trials :
† Phase III
§ Never to phase III
Cough and cold preparations (R05 )
Expectorants
Althea root
Antimony pentasulfide
Creosote
Guaiacolsulfonate
Guaifenesin (+ oxomemazine )
Ipecacuanha (Syrup of ipecac )
Levoverbenone
Potassium iodide
Senega
Tyloxapol
Ammonium Chloride
Mucolytics Cough suppressants
Opium alkaloids,opioids , and derivatives
Acetyldihydrocodeine
Benzylmorphine
Butorphanol
Codeine #
Dextromethorphan
Dihydrocodeine
Dimemorfan
Droxypropine
Ethylmorphine
Heroin
Hydrocodone
Hydromorphone
Isoaminile
Laudanum
Levomethadone
Levopropoxyphene
Methadone
Nicocodeine
Nicodicodeine
Normethadone
Noscapine
Pholcodine
Thebacon
Tipepidine
Other
# WHO-EM
‡ Withdrawn from market
Clinical trials :
† Phase III
§ Never to phase III
MOR
Unknown/unsorted: Cannabidiol
Coronaridine
Cyproterone acetate
Tabernanthine
Tetrahydrocannabinol
DOR
Unknown/unsorted: 18-MC
Cannabidiol
Coronaridine
Cyproterone acetate
Tabernanthine
Tetrahydrocannabinol
KOR
Unknown/unsorted: Akuammicine
Akuammine
Coronaridine
Cyproterone acetate
Ibogamine
Tabernanthine
NOP Unsorted
β-Casomorphins
Amidorphin
Cytochrophin-4
Gliadorphin (gluteomorphin)
Gluten exorphins
Hemorphins
Kava constituents
NEM
Neoendorphins
Nepetalactone (catnip )
Rubiscolins
Others
Enkephalinase inhibitors : Amastatin
Candoxatril
D -Phenylalanine
Ecadotril (sinorphan)
Kelatorphan
Racecadotril (acetorphan)
RB-101
RB-120
RB-3007
Selank
Semax
Spinorphin
Thiorphan
Tynorphin
Ubenimex (bestatin)
Propeptides: β-Lipotropin (proendorphin)
Prodynorphin
Proenkephalin
Proopiomelanocortin (POMC)
Others: Kyotorphin (met-enkephalin releaser/degradation stabilizer)